Study Objective: The prevalence of supine-dependent obstructive sleep apnea (sdOSA) in a general population ranges from 20% to 60%, depending on the criteria used. Currently, the prevalence and evolution of sdOSA once oral appliance therapy with a mandibular advancement device (OA m ) has started is unknown. In addition, literature on the correlation between sdOSA and treatment success with OA m is not unequivocal. The fi rst purpose of this study was to assess the prevalence of sdOSA before and under OA m therapy. Second, the conversion rate from non-sdOSA to sdOSA during OA m therapy was evaluated. The third and fi nal goal was to analyze the correlation between sdOSA and treatment success with OA m therapy in the patient population. Methods: Two hundred thirty-seven consecutive patients (age 48 ± 9 years; male/female ratio 173/64; AHI 20.1 ± 14.7 events/h; BMI 27.2 ± 4.3 kg/m 2 ) starting OA m therapy were included.
O bstructive sleep apnea (OSA) is a prevalent disorder characterized by repetitive upper airway collapse or upper airway narrowing during sleep, often resulting in hypoxemia and arousal from sleep. 1 It has been described that undiagnosed or untreated OSA is associated with excessive daytime sleepiness, impaired cognitive performance, a reduced quality of life, an increased risk of motor vehicle and occupational accidents, and cardiovascular and cerebrovascular morbidity and mortality. 2, 3 The severity of OSA is expressed by the apnea-hypopnea index (AHI), defi ned as the average number of apneas and hypopneas per hour of sleep. 1, 4 In so-called supine-dependent OSA (sdOSA) patients the breathing abnormalities are clustered mainly in the supine posture, whereas non-sdOSA patients have breathing abnormalities in both the lateral and supine postures. [5] [6] [7] [8] Therefore, it could be of clinical importance to split up the total AHI according to sleep position with the supine AHI (defi ned as the number of apneas and hypopneas per hour of sleep spent in supine position) and the non-supine AHI (defi ned as the number of apneas and hypopneas per hour of sleep spent in the non-supine position). 9 The most frequently and widely used defi nition is a supine AHI ≥ twice as high as the non-supine AHI and was fi rst described by Cartwright et al. 5 The prevalence of sdOSA in a general population ranges the literature from 46% to 80%, which was comparable to the prevalence of sdOSA in the general population. 13, 16, 17 These results, however, do not reveal the evolution of sdOSA once OA m has started, and the prevalence of sdOSA under OA m therapy is still unknown. Interestingly, in some patients sdOSA and non-sdOSA are dynamic phenotypes 8 : weight reduction may convert a non-sdOSA patient into sdOSA. 18 In addition, it is stated that any OSA treatment that could not completely eliminate all breathing abnormalities leaves the patient with a residual OSA that is mainly supine-dependent. 8 With CPAP therapy it was reported that a severe non-sdOSA patient converted to sdOSA during a CPAP titration night. 19 In this study, the patient had a non-sdOSA when CPAP pressure was low. When CPAP pressure was higher in the second part of the night, the patient became clearly supine-dependent, with no respiratory events while sleeping on his side, but as soon as he shifted to the supine sleeping position, respiratory events appeared. However, it is unknown whether OA m therapy also leads to such a conversion.
In the past, retrospective analyses of clinical, physiological, and polysomnographic variables were performed in order to identify predictors of treatment success with OA m therapy. There is evidence to support the findings that OA m therapy is more likely to be successful in younger female patients, with lower body mass index, a smaller neck circumference, and less severe sleep apnea. 13, [20] [21] [22] [23] In addition, the majority of studies evaluating the effect of sleep position on OA m efficacy have reported that OA therapy is more efficacious in patients with sdO-SA. 13, 16, 17, [24] [25] [26] However, other studies did not find a difference in success rates between non-sdOSA and sdOSA patients.
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The first purpose of the present study was to evaluate the prevalence of sdOSA before and under OA m therapy. The second objective was to describe the conversion rate from nonsdOSA to sdOSA during OA m therapy. Because the literature on the correlation between sdOSA and treatment success with OA m is not unequivocal, the final goal of this study was to analyze the correlation between sdOSA and treatment success in our patient population.
METHODS
All patients in this retrospective analysis were diagnosed with OSA based on a recent polysomnography and underwent a full medical and dental examination including orthopantomography. Patients were not judged suitable for oral appliance therapy if they suffered from any preexisting temporomandibular joint (TMJ) dysfunction, if their dental status or periodontal health precluded them from wearing an oral appliance, or if they were fully edentulous. Three hundred six consecutive adult OSA patients received oral appliance therapy with a custom-made titratable OA m .
The study protocol was approved by the Institutional Review Board of the Antwerp University Hospital, Belgium (B300201110946).
Oral Appliance
Custom-made titratable OA m (Respident Butterfly, Dormoco, Belgium 29 or SomnoDent Flex, Somnomed AG, Australia 30 ) was used. Patients were instructed to gradually titrate the OA m until subjective resolution of symptoms occurred, or until the maximum comfortable limit was reached. 30, 31 The titration procedure lasted on average 137 ± 97 days.
Polysomnography
Patients were diagnosed with OSA based on an overnight level-I polysomnography (PSG) and were invited to undergo a PSG with OA m after the titration procedure. PSG included the recording of electroencephalography (EEG), right and left electrooculography (EOG), submental electromyography (EMG), electrocardiography (ECG), and oxygen saturation using pulse oximetry with a finger probe. Respiratory variables were recorded, including nasal airflow by means of an external thermistor and nasal pressure by using a nasal pressure canula. Respiratory effort was measured using respiratory inductance plethysmography. Body position was monitored using a piezoelectric sensor and was used to differentiate between supine, right lateral, left lateral, prone, and upright sleeping position. Snoring was recorded qualitatively by a microphone.
An apnea was defined as a total cessation of airflow > 10 s, and a hypopnea as decrease of airflow ≥ 50% from baseline, or a clear decrease in airflow associated with an oxygen desaturation ≥ 4% and/or an arousal for ≥ 10 seconds.
1 Baseline was defined as the mean amplitude of stable breathing in the 2 min preceding onset of the event (in individuals with a stable breathing pattern during sleep) or the mean amplitude of the 3 largest breaths in the 2 preceding min where breathing pattern was unstable. The severity of OSA was expressed by the AHI, defined as the number of apneas and hypopneas per hour of sleep. The diagnosis of OSA was confirmed if the AHI was > 5 events per hour of sleep. 
Treatment Outcome Measures
Complete response was defined as a decrease in AHI to < 5/h with the OA m . Partial response was defined as a reduction in AHI with the OA m ≥ 50% compared to baseline.
Supine-Dependent Obstructive Sleep Apnea
Supine AHI is defined as the number of apneas and hypopneas per hour of sleep spent in supine position, while nonsupine AHI is defined as the number of apneas and hypopneas per hour of sleep spent in the non-supine position. 13 Different definitions of sdOSA are described in literature. The most frequently used definition for defining sdOSA were established by Cartwright et al. as a supine AHI that is at least twice as high as a non-supine AHI 5 . Mador et al. 10 defined SDOSA as an AHI of < 5 events/h in the non-supine position and a supine AHI of at least twice as high as the non-supine AHI, with a 15-min threshold for sleep in both postures. Marklund et al. 25 defined sdOSA patients as having a supine AHI ≥ 10 events/h together with a non-supine AHI of < 10 events/h. The results of this study will be evaluated according to these different definitions.
Statistical Analysis
Data analysis was performed using SPSS (SPSS version 17.0, SPSS Inc., Chicago, IL, USA). Descriptive statistics for characteristics of patients were presented as means ± standard deviation (SD). The Shapiro-Wilk test was performed to assess the normality of distribution.
Continuous data between groups were compared with a nonparametric Mann-Whitney U test. A Wilcoxon signed-rank test was used to compare measurements at baseline and at evaluation with OA m . A multiple logistic regression model was used to study the effect of supine-dependent OSA with oral appliance efficacy, correcting for age, gender, baseline AHI, and baseline BMI. Odds ratios and corresponding 95% confidence intervals were reported.
RESULTS

Study Population and Prevalence of Supine-Dependent
OSA Prior to OA m Therapy
Three hundred six patients with an established diagnosis of OSA and consecutively receiving treatment with a custommade titratable OA m were included. Anthropomorphic and polysomnographic data prior to OA m therapy were collected in all 306 patients, of whom 237 patients (age 48 ± 9 years; male/ female ratio 173:64; AHI 20.1 ± 14.7/h sleep with a range from 5/h to 97.1/h; BMI 27.2 ± 4.3) had a full dataset at baseline, including supine-dependent parameters. Patients were subdivided in 2 groups following the presence or absence of sdOSA according to Cartwright's definition ( Table 1) . There were no statistically significant differences between these 2 groups for these baseline parameters. One hundred sixty of these 237 patients (67.5%) could be defined as patients with sdOSA following Cartwright's definition. The prevalences of sdOSA before OA m therapy following the definitions of Marklund 19 and Mador 10 were 45.6% and 27.0%, respectively ( Table 2) .
OA m Efficacy
The overall effect of OA m therapy was assessed using fullnight PSG with OA m . In 183 patients, polysomnographic data before and under OA m therapy were available. Overall, the OA m was effective in reducing the AHI from 20.8 ± 14.1/h at baseline to 9.9 ± 8.8/h with (p < 0.05). A significant reduction in both supine AHI, from 35.4 ± 26.0 to 15.6 ± 17.7/h with OA m (p < 0.05), and in non-supine AHI, from 13.5 ± 14.2 to 6.9 ± 7.8 with OA m (p < 0.05) was noted. In addition, both REM AHI and NREM AHI were significantly reduced under OA m therapy: from 26.8 ± 18.7 to 18.1 ± 14.8/h (p < 0.05), and from 18.1 ± 16.1 to 7.6 ± 9.1 (p < 0.05), respectively. Complete and partial response was achieved in 39.9% (73 patients) and 60.1% (110 patients), respectively.
Prevalence of Supine-Dependent OSA under OA m Therapy
In 183 patients, polysomnographic data before and under OA m therapy were available. The prevalence of residual sdOSA under OA m therapy in this study population ranged from 17.5% to 33.9%, depending on the criteria used ( Table 2) .
Conversion from Non-Supine-Dependent to SupineDependent OSA during OA m Therapy One hundred ten of 183 patients did not achieve a complete response under OA m therapy and suffered therefore from residual OSA with an AHI > 5/h under OA m therapy. In 34 of these patients, the OSA was non-supine-dependent following Cartwright's criterion. In 12 of these patients (35%), OSA became supine-dependent under OA m therapy. In contrast, in almost two-third of patients with sdOSA before start of OA m therapy, the OSA remained supine-dependent under therapy. Following Mador's criteria, 20 of 86 (23%) non-sdOSA patients at baseline became supine-dependent under OA m therapy. Twenty-four of 64 (37.5%) non-sdOSA patients became sdOSA patients under OA m therapy following Marklund's criteria. The data are presented as mean ± standard deviation or as total number. 
OA m Efficacy According to Supine-Dependency
OA m therapy was effective in reducing the AHI in both sdOSA and non-sdOSA patients following Cartwright's definition, from 18.8 ± 11.4/h at baseline to 9.0 ± 7.6/h (p < 0.05) in supine-dependent patients and from 25.1 ± 19.8/h at baseline to 11.7 ± 11.0/h (p < 0.05) in non-sdOSA patients (Figure 1) . A significant reduction in supine AHI, non-supine AHI, REM AHI, and NREM AHI was noted in all patients-sdOSA as well as nonsdOSA patients. However, in sdOSA, the decrease in supine AHI (25.0 ± 26.4/h) was significantly higher than that of non-sdOSA patients (8.4 ± 24.4/h; p < 0.05), whereas the decrease in nonsupine AHI was higher in non-sdOSA patients (14.8 ± 18.3/h vs 3.0 ± 8.9/h; p < 0.05). The decrease in REM AHI and NREM AHI was not significantly different in sdOSA vs non-sdOSA patients.
Complete response rate for the patients with versus without sdOSA at baseline, according to the different criteria for sdOSA, is shown in Table 3 . It was noted that the complete response rate was slightly higher in patients without sdOSA at baseline than in patients with sdOSA at baseline; this was not statistically significant for the definition of Cartwright and Marklund but was significant for Mador's criterion (p < 0.05).
Correlation of sdOSA with Partial Response and Complete Response using a Logistic Regression Model
According to a multiple logistic model including sdOSA and the variables age, gender, baseline BMI and baseline AHI, the presence of sdOSA was no predictor of partial or complete re- 
DISCUSSION
In previous studies evaluating the effect of sleep position on OA m therapy, it was shown that the prevalence of sdOSA in patients starting OA m therapy ranged from 46% to 80%. In addition, it has been shown that sdOSA is a dynamic phenotype under varying circumstances, such as weight reduction and unsuccessful CPAP therapy. However, the effect of OA m therapy on sdOSA has not been known.
The results of this study first demonstrate that sdOSA is relatively common in patients starting OA m therapy, with a prevalence ranging between 27.0% and 67.5%, depending on the definition used ( Table 2 ). In patients who did not achieve complete response, the prevalence of sdOSA ranges from 17.5% to 33.9%. The second objective was to describe the conversion rate of the sdOSA phenotype under OA m therapy and revealed that 23% to 37.5% shifted from non-sdOSA to sdOSA. The final goal was to analyze the correlation between sdOSA and a successful OA m treatment; statistical analysis showed that the presence of sdOSA at baseline was no predictor of OA m efficacy using a logistic regression model.
OA m therapy was effective in reducing the AHI in both supine-dependent and non-supine-dependent OSA patients. However, the decrease in supine AHI was significantly higher in sdOSA patients, whereas the decrease in non-supine AHI was higher in the non-sdOSA patients. This difference between the two patient groups is probably due to the fact that the supine AHI is significantly higher in patients with sdOSA at baseline, whereas the non-supine AHI is higher at baseline in patients with non-sdOSA ( Table 1 In the literature, different definitions of sdOSA are used. 5, 10, 25, 30 The application of three different sdOSA criteria leads to a wide range in prevalence and makes it hard to compare the prevalence of sdOSA with respect to other prevalence studies. However, Cartwright was the first to categorize patients as supine-dependent if the supine AHI was at least twice as high as the non-supine AHI. 5 This criterion is the most widely and frequently used in literature. Some authors have made changes to this definition, such as Mador 10 whose criterion of supine-dependent OSA is derived from Cartwright's criterion.
It was noted that almost one of three patients shifted from a non-sdOSA at baseline to sdOSA under OA m therapy. A possible explanation for this high conversion rate is that sdOSA is a dynamic phenotype associated with younger age, lower BMI, and less severe OSA. 6 It has been reported previously that decreasing body weight may shift a patients with non-sdOSA to sdOSA and that by increasing body weight a patient with sdOSA may be shifted into non-sdOSA. 18 In addition, any OSA therapy that is not able to completely eliminate all breathing abnormalities leaves the patient with a residual OSA, which is less severe than the initial OSA and is therefore probable more supine-dependent. This conversation rate was described under CPAP therapy and is now described for OA m therapy. The exact underlying pathophysiologic mechanism of this dynamic phenotype is unknown. However, one could hypothesize that differences in upper airway collapsibility play a major role. 32, 33 A possible mechanism is that young, thin patients have initially a low collapsibility of the upper airway, with respiratory events being only present while sleeping in the supine position where the gravitational forces increases the tendency of upper airway collapse. In general, the tendency of upper airway collapse increases with higher age and higher BMI. As a consequence, such patients could develop respiratory events in the lateral position with increasing age and/or weight gain.
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Previous studies of positional therapies using the tennis ball technique showed a compliance of less than 40% after long-term follow-up. [35] [36] [37] The main reason for discontinuation were discomfort, backache, and no improvement in sleep quality and was attributed to the use of bulky devices placed on patient's back to discourage a supine sleeping position. 38 Recently, a new neck-worn device that vibrates when in supine position has shown promising results in overcoming these compliance aspects. 39 In the present study, the presence of sdOSA has no effect on OA m efficacy. This finding contrasts previous studies where it was found that the OA m efficacy may be influenced by sleep position in a way that patients with sdOSA have better treatment outcomes under OA m therapy. 13, 16, 17, [24] [25] [26] Only one other study has found no effect of body position on the outcome of OA therapy. 27 This topic needs to be further elucidated in larger prospective randomized and controlled clinical studies to better understand OA m efficacy across all sleep stages and body positions.
It is assumed that the amount of supine sleep varies between nights. 40 In patients with position-dependent OSA, this can lead to a possible night-to-night variation in AHI and OSA severity due to the discrepancy between supine and non-supine AHI. 41, 42 In addition, the relationship between supine sleep time in the sleep lab during a full polysomnography and the supine sleep time at home in the individual patient is yet unknown. 42 This clearly illustrates the clinical relevance of defining supinedependency in patients; therefore, it is recommended to use supine-dependent data in clinical practice, particularly in aid of treatment choices and follow-up of patients with positiondependent sleep apnea. 41 The present study has its limitations. The first limitation is that this is a retrospective analysis. This means there were many participants with missing data at baseline and that there was a relatively high participation loss. Second, two types of oral appliances were used. However, statistical analysis revealed that there was no difference in success rate and sdOSA prevalence between the two different oral appliances.
Despite these limitations, the authors believe that the relatively high conversion rate of sdOSA under OA m therapy as well as the high prevalence of sdOSA under OA m therapy have important clinical relevance. Avoidance of the supine sleeping position could have an influence on the overall AHI in those patients, and positional therapy should be considered as a treatment option or as additive treatment in patients with residual sdOSA under OA m therapy.
CONCLUSION
In conclusion, the findings of this study show that the prevalence of sdOSA before and during OA m therapy is clinically relevant. Second, one-third of patients shift from non-supine-dependent to sdOSA. Finally, treatment success was not statistically significant correlated with the presence of sdOSA at baseline.
